Lazard Capital Boosts Target on Affymax (AFFY) to $20 Ahead of Likely FDA Approval

Lazard Capital boosted its price target on Affymax, Inc. (NASDAQ: AFFY) from $11 to $20 ahead of the Peginesatide PDUFA date on March 27. The firm expects the FDA to follow the advice of the OCAD panel and recommend approval.

The firm maintained their Buy rating.

For an analyst ratings summary and ratings history on Affymax, Inc. click here. For more ratings news on Affymax, Inc. click here.

Shares of Affymax, Inc. closed at $11.18 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities
• Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities